Cyclic Peptide Growth Factor Analogs for Tissue Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for tissue regeneration, such as using recombinant growth factors, often face challenges including poor stability, slow activity, and potential side effects, limiting their effectiveness in promoting rapid and efficient tissue repair and regeneration.
Innovation Solution
Development of cyclic compounds and bioactive carriers that bind to growth factor receptors, enhancing stem cell differentiation and tissue regeneration by modifying the extracellular microenvironment to promote rapid and efficient differentiation of mesenchymal stem cells into specific cell types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant growth factors are used to promote tissue regeneration, then tissue repair capability is improved, but treatment time is extended and side effects increase
Solution Approach 1:
The patent modifies the chemical structure of growth factors by creating cyclic analogs with altered peptide bonds (replacing amide bonds with aminoethylamide or aminopropylamide linkages). These structural parameter changes enhance the stability and biological activity of the growth factors, enabling faster tissue regeneration while reducing the required treatment duration and minimizing side effects associated with conventional recombinant growth factors.
2Reliability
If recombinant growth factors are used to promote tissue regeneration, then tissue repair capability is improved, but stability of the treatment is reduced
Solution Approach 1:
The cyclic structure of the growth factor analogs fundamentally changes the physical and chemical parameters of the molecule. The cyclic peptide backbone provides enhanced conformational stability and resistance to proteolytic degradation compared to linear recombinant growth factors. This structural modification maintains the bioactive conformation while improving overall stability, thereby enhancing tissue repair capability with more stable treatment.
3Reliability
If conventional growth factor methods are used, then tissue regeneration is promoted, but manufacturing complexity increases
Solution Approach 1:
The cyclic growth factor analogs are designed as stable, long-acting molecules that replace the need for repeated administrations of conventional growth factors. This approach simplifies manufacturing by eliminating the need for complex refrigeration and handling protocols required for unstable recombinant proteins, while maintaining effective tissue regeneration. The enhanced stability allows for simpler storage and administration protocols.
Data Source
AI summary
The present disclosure provides a cyclic peptide, or a variant or analog thereof, or a cyclic peptidomimetic, with between 15 and 35 amino acids, having a growth factor receptor-binding capability and comprising a peptide with four amino acids PEP1, and a peptide with five amino acids PEP2; wherein PEP1 is selected from the group consisting of SAIS, SSLS, NAIS, SATS, SPIS, EPIS, SPIN, KPLS, EPLP, EPLT, SNIT, RSVK and RPVQ; and wherein PEP2 is selected from the group consisting of LKNYQ, LKVYP, LKKYR, LRKHR, LKYHY, KFKYE, YGKIP, YKQYE, DHHKD, EQLSN, IGEMS, LGEMS, KEVQV and KKATV.